Doctor profile · Federal record

Dr. Richard Bryan, MD

Rheumatology Physician (CMS: Rheumatology) · Queensbury, NY

  • NPI 1508952953
  • Accepts Medicare
  • MIPS 90.6 / 100 · 2023
  • 23 yrs in practice
  • Male
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
161 Carey RD
Queensbury, NY 128047821
(518) 824-8610
fax (518) 824-2390
Mailing address
9 Carey RD
Queensbury, NY 128047880

Credentials & registration

NPPES · NUCC
NPI registered
October 2006 — 20 yrs on file
Profile last updated
July 21, 2022
Year of graduation
2003 — 23 yrs since
Specialty taxonomy
207RR0500X — NUCC code
State license (1)
New York #253151
Medicaid
NY #03273558

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1508952953. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
32,298
Distinct HCPCS
10
Medicare allowed
$739,956
HCPCS Description Services Patients Avg allowed
J1602 Injection, golimumab, 1 mg, for intravenous use 19,099 27 $13
J1745 Injection, infliximab, excludes biosimilar, 10 mg 8,467 29 $33
J0897 Injection, denosumab, 1 mg 1,920 29 $23
99214 Established patient office or other outpatient visit, 30-39 minutes 813 373 $123
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 580 59 $1
96415 Administration of chemotherapy into vein, each additional hour 358 36 $27
96413 Administration of chemotherapy into vein, 1 hour or less 195 43 $122
J7050 Infusion, normal saline solution, 250 cc 176 37 $1
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 164 44 $61
36415 Insertion of needle into vein for collection of blood sample 162 82 $7

In context: peer comparison

Among 1 peers in this city , average services per provider: 2,018. This provider delivers 16× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$30,957
Transactions
193
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Mallinckrodt Hospital Products Inc. 71 $28,261.02
ABBVIE INC. 33 $820.51
Janssen Biotech, Inc. 35 $438.11
AstraZeneca Pharmaceuticals LP 11 $375.46
GlaxoSmithKline, LLC. 9 $232.76
UCB, Inc. 10 $190.88
PFIZER INC. 9 $170.15
Janssen Scientific Affairs, LLC 1 $136.76
Amgen Inc. 4 $87.34
Novartis Pharmaceuticals Corporation 3 $66.77
Organon Llc 3 $57.60
Sandoz Inc. 1 $29.67
Teva Pharmaceuticals USA, Inc. 1 $25.07
SCILEX PHARMACEUTICALS INC. 1 $24.96
Fidia Pharma USA Inc. 1 $23.85

By nature of payment

Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
$24,150
Food and Beverage
$4,068
Travel and Lodging
$2,699
Gift
$41

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
1,015
Patients
339
Total drug cost
$2,878,699
Drug Type Claims Patients Total cost
Prednisone Generic 231 105 $1,927
Methotrexate (Methotrexate Sodium) Brand 113 42 $3,143
Tramadol Hcl Generic 107 53 $437
Celecoxib Generic 101 36 $4,777
Hydroxychloroquine Sulfate Generic 94 29 $3,355
Humira(Cf) Pen (Adalimumab) Brand 84 17 $566,993
Rinvoq (Upadacitinib) Brand 60 14 $392,725
Diclofenac Sodium Generic 48 27 $3,503
Meloxicam Generic 28 16 $154
Clonazepam Generic 27 0 $94

Frequently asked questions

Auto-generated from federal data
What is Dr. Richard Bryan's medical specialty?
Dr. Richard Bryan practices Rheumatology Physician in Queensbury, NY.
Where does Dr. Richard Bryan practice?
Dr. Richard Bryan practices at 161 Carey RD, Queensbury, NY 128047821. Office phone: 5188248610.
What is Dr. Richard Bryan's NPI?
Dr. Richard Bryan's National Provider Identifier (NPI) is 1508952953, issued by NPPES.
Does Dr. Richard Bryan accept Medicare assignment?
Yes. Dr. Richard Bryan accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Richard Bryan commonly perform?
Top Medicare-reported procedures in 2023: Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, infliximab, excludes biosimilar, 10 mg (HCPCS J1745); Injection, denosumab, 1 mg (HCPCS J0897). Source: CMS Medicare Physician & Other Practitioners file.